Toronto, Ontario–(Newsfile Corp. – March 3, 2025) – DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) (“DiagnaMed”, “DMED”, or the “Company”), a leading provider of cutting-edge technology solutions for the hydrogen and life sciences industries, today announced in a significant advancement for rare disease research, the Company has been granted Orphan Drug Designation (ODD) for molecular hydrogen in […]